Novo Nordisk Sees First-Half U.S. Launch of Tresiba

Play

Jan. 31 (Bloomberg) -- Jesper Brandgaard, chief financial officer of Novo Nordisk A/S, discusses the company's fourth-quarter profit reported today, growth expectations for the insulin market and the outlook for U.S. approval of its Tresiba diabetes treatment. He speaks from Copenhagen with Francine Lacqua on Bloomberg Television's "The Pulse." (Source: Bloomberg)